{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T21:23:24Z","timestamp":1781213004502,"version":"3.54.1"},"reference-count":120,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2012,5,1]],"date-time":"2012-05-01T00:00:00Z","timestamp":1335830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medical Clinics of North America"],"published-print":{"date-parts":[[2012,5]]},"DOI":"10.1016\/j.mcna.2012.05.001","type":"journal-article","created":{"date-parts":[[2012,6,15]],"date-time":"2012-06-15T19:54:45Z","timestamp":1339790085000},"page":"497-523","source":"Crossref","is-referenced-by-count":8,"title":["Immunotherapies in Neurologic Disorders"],"prefix":"10.1016","volume":"96","author":[{"given":"Donna","family":"Graves","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Vernino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.mcna.2012.05.001_bib1","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/S0303-8467(02)00036-7","article-title":"The worldwide prevalence of multiple sclerosis","volume":"104","author":"Pugliatti","year":"2002","journal-title":"Clin Neurol Neurosurg"},{"issue":"1","key":"10.1016\/j.mcna.2012.05.001_bib2","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.neuron.2006.09.011","article-title":"The neurobiology of multiple sclerosis: genes, inflammation, and neurodegeneration","volume":"52","author":"Hauser","year":"2006","journal-title":"Neuron"},{"issue":"11","key":"10.1016\/j.mcna.2012.05.001_bib3","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1212\/01.WNL.0000096175.39831.21","article-title":"Effect of relapses on development of residual deficit in multiple sclerosis","volume":"61","author":"Lublin","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.mcna.2012.05.001_bib4","series-title":"Multiple sclerosis therapeutics","first-page":"515","article-title":"High-dose methylprednisolone in the treatment of multiple sclerosis","author":"Fox","year":"2007"},{"issue":"6","key":"10.1016\/j.mcna.2012.05.001_bib5","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1002\/1531-8249(199912)46:6<878::AID-ANA10>3.0.CO;2-Q","article-title":"A\u00a0randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease","volume":"46","author":"Weinshenker","year":"1999","journal-title":"Ann Neurol"},{"issue":"1","key":"10.1016\/j.mcna.2012.05.001_bib6","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1191\/1352458504ms978sr","article-title":"A\u00a0randomized, double-blind, placebo-controlled pilot study of i.v. immune globulins in combination with i.v. methylprednisolone in the treatment of relapses in patients with MS","volume":"10","author":"Visser","year":"2004","journal-title":"Mult Scler"},{"issue":"11","key":"10.1016\/j.mcna.2012.05.001_bib7","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1212\/01.WNL.0000145798.61383.39","article-title":"IV immunoglobulins as add-on treatment to methylprednisolone for acute relapses in MS","volume":"63","author":"Sorensen","year":"2004","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.mcna.2012.05.001_bib8","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1056\/NEJM199807303390501","article-title":"Rate of pregnancy-related relapse in multiple sclerosis. Pregnancy in Multiple Sclerosis Group","volume":"339","author":"Confavreux","year":"1998","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.mcna.2012.05.001_bib9","first-page":"1133","article-title":"Effect of intravenous immunoglobulin treatment on pregnancy and postpartum-related relapses in multiple sclerosis","volume":"251","author":"Achiron","year":"2004","journal-title":"J\u00a0Neurol"},{"issue":"3","key":"10.1016\/j.mcna.2012.05.001_bib10","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMoa011341","article-title":"A\u00a0longitudinal study of abnormalities on MRI and disability from multiple sclerosis","volume":"346","author":"Brex","year":"2002","journal-title":"N\u00a0Engl J Med"},{"issue":"9268","key":"10.1016\/j.mcna.2012.05.001_bib11","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1016\/S0140-6736(00)04725-5","article-title":"Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study","volume":"357","author":"Comi","year":"2001","journal-title":"Lancet"},{"issue":"13","key":"10.1016\/j.mcna.2012.05.001_bib12","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1056\/NEJM200009283431301","article-title":"Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group","volume":"343","author":"Jacobs","year":"2000","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.mcna.2012.05.001_bib13","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1212\/01.wnl.0000237641.33768.8d","article-title":"Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes","volume":"67","author":"Kappos","year":"2006","journal-title":"Neurology"},{"issue":"9700","key":"10.1016\/j.mcna.2012.05.001_bib14","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1016\/S0140-6736(09)61259-9","article-title":"Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial","volume":"374","author":"Comi","year":"2009","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.mcna.2012.05.001_bib15","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1212\/WNL.43.4.655","article-title":"Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial","volume":"43","year":"1993","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.mcna.2012.05.001_bib16","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/ana.410390304","article-title":"Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)","volume":"39","author":"Jacobs","year":"1996","journal-title":"Ann Neurol"},{"issue":"7","key":"10.1016\/j.mcna.2012.05.001_bib17","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1212\/WNL.45.7.1268","article-title":"Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group","volume":"45","author":"Johnson","year":"1995","journal-title":"Neurology"},{"issue":"9139","key":"10.1016\/j.mcna.2012.05.001_bib18","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/S0140-6736(98)03334-0","article-title":"Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing\/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group","volume":"352","year":"1998","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.mcna.2012.05.001_bib19","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa044397","article-title":"A\u00a0randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis","volume":"354","author":"Polman","year":"2006","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.mcna.2012.05.001_bib20","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1056\/NEJMoa044396","article-title":"Natalizumab plus interferon beta-1a for relapsing multiple sclerosis","volume":"354","author":"Rudick","year":"2006","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.mcna.2012.05.001_bib21","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1056\/NEJMoa0909494","article-title":"A\u00a0placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis","volume":"362","author":"Kappos","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.mcna.2012.05.001_bib22","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1056\/NEJMoa0907839","article-title":"Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis","volume":"362","author":"Cohen","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.mcna.2012.05.001_bib23","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1212\/01.WNL.0000034080.43681.DA","article-title":"Randomized, comparative study of interferon \u03b2-1a treatment regimens in MS THE EVIDENCE Trial","volume":"59","author":"Panitch","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/j.mcna.2012.05.001_bib24","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0140-6736(02)08430-1","article-title":"Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomized multicentre study (INCOMIN)","volume":"359","author":"Durelli","year":"2002","journal-title":"The Lancet Neurology"},{"key":"10.1016\/j.mcna.2012.05.001_bib25","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/S1474-4422(08)70200-X","article-title":"Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial","volume":"7","author":"Mikol","year":"2008","journal-title":"The Lancet Neurology"},{"key":"10.1016\/j.mcna.2012.05.001_bib26","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/S1474-4422(09)70226-1","article-title":"250 mcg or 500 mcg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective randomized, multicentre study","volume":"8","author":"O'Connor","year":"2009","journal-title":"The Lancet Neurology"},{"issue":"23","key":"10.1016\/j.mcna.2012.05.001_bib27","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1212\/01.wnl.0000345970.73354.17","article-title":"Efficacy of treatment of MS with IFN \u03b2-1b or glatiramer acetate by monthly brain MRI in the BECOME study","volume":"72","author":"Cadavid","year":"2009","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.mcna.2012.05.001_bib28","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/ana.22366","article-title":"Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria","volume":"69","author":"Polman","year":"2011","journal-title":"Ann Neurol"},{"issue":"4","key":"10.1016\/j.mcna.2012.05.001_bib29","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.clinthera.2006.04.013","article-title":"Management of worsening multiple sclerosis with mitoxantrone: a review","volume":"28","author":"Fox","year":"2006","journal-title":"Clin Ther"},{"issue":"3","key":"10.1016\/j.mcna.2012.05.001_bib30","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1177\/1352458507084264","article-title":"Natural history of secondary-progressive multiple sclerosis","volume":"14","author":"Tremlett","year":"2008","journal-title":"Mult Scler"},{"issue":"9350","key":"10.1016\/j.mcna.2012.05.001_bib31","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1016\/S0140-6736(02)12023-X","article-title":"Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial","volume":"360","author":"Hartung","year":"2002","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.mcna.2012.05.001_bib32","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/ana.21079","article-title":"Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial","volume":"61","author":"Wolinsky","year":"2007","journal-title":"Ann Neurol"},{"issue":"4","key":"10.1016\/j.mcna.2012.05.001_bib33","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1002\/ana.21867","article-title":"Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial","volume":"66","author":"Hawker","year":"2009","journal-title":"Ann Neurol"},{"issue":"2","key":"10.1016\/j.mcna.2012.05.001_bib34","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/nrneurol.2010.198","article-title":"Therapies for multiple sclerosis: considerations in the pediatric patient","volume":"7","author":"Banwell","year":"2011","journal-title":"Nat Rev Neurol"},{"issue":"1","key":"10.1016\/j.mcna.2012.05.001_bib35","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s11940-008-0007-z","article-title":"Neuromyelitis optica","volume":"10","author":"Wingerchuk","year":"2008","journal-title":"Curr Treat Options Neurol"},{"issue":"5","key":"10.1016\/j.mcna.2012.05.001_bib36","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1212\/01.WNL.0000049912.02954.2C","article-title":"Neuromyelitis optica: clinical predictors of a relapsing course and survival","volume":"60","author":"Wingerchuk","year":"2003","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.mcna.2012.05.001_bib37","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1212\/WNL.53.5.1107","article-title":"The clinical course of neuromyelitis optica (Devic's syndrome)","volume":"53","author":"Wingerchuk","year":"1999","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.mcna.2012.05.001_bib38","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1177\/1352458506071174","article-title":"Therapeutic efficacy of plasma exchange in NMO-IgG-positive patients with neuromyelitis optica","volume":"13","author":"Watanabe","year":"2007","journal-title":"Mult Scler"},{"issue":"12","key":"10.1016\/j.mcna.2012.05.001_bib39","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1212\/WNL.0b013e3181b879be","article-title":"Plasma exchange for acute attacks of CNS demyelination: predictors of improvement at 6 months","volume":"73","author":"Llufriu","year":"2009","journal-title":"Neurology"},{"issue":"8","key":"10.1016\/j.mcna.2012.05.001_bib40","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1111\/j.1468-1331.2010.03066.x","article-title":"EFNS guidelines on diagnosis and management of neuromyelitis optica","volume":"17","author":"Sellner","year":"2010","journal-title":"Eur J Neurol"},{"issue":"8","key":"10.1016\/j.mcna.2012.05.001_bib41","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1001\/archneurol.2010.188","article-title":"Interferon beta treatment in neuromyelitis optica: increase in relapses and aquaporin 4 antibody titers","volume":"67","author":"Palace","year":"2010","journal-title":"Arch Neurol"},{"issue":"5","key":"10.1016\/j.mcna.2012.05.001_bib42","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1111\/j.1468-1331.2009.02897.x","article-title":"Different responses to interferon beta-1b treatment in patients with neuromyelitis optica and multiple sclerosis","volume":"17","author":"Uzawa","year":"2010","journal-title":"Eur J Neurol"},{"issue":"1","key":"10.1016\/j.mcna.2012.05.001_bib43","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jns.2006.10.008","article-title":"Interferon beta-1b exacerbates multiple sclerosis with severe optic nerve and spinal cord demyelination","volume":"252","author":"Warabi","year":"2007","journal-title":"J\u00a0Neurol Sci"},{"issue":"2","key":"10.1016\/j.mcna.2012.05.001_bib44","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1212\/WNL.0b013e318219dde5","article-title":"IFNbeta-1b may severely exacerbate Japanese opticspinal MS in neuromyelitis optica spectrum: Japanese optic-spinal MS: is it MS or neuromyelitis optica and does the answer dictate treatment?","volume":"77","author":"Bomprezzi","year":"2011","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.mcna.2012.05.001_bib45","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1177\/1352458506070732","article-title":"Immunosuppressive therapy is more effective than interferon in neuromyelitis optica","volume":"13","author":"Papeix","year":"2007","journal-title":"Mult Scler"},{"issue":"7","key":"10.1016\/j.mcna.2012.05.001_bib46","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1212\/WNL.0b013e31822a2780","article-title":"Azathioprine: tolerability, efficacy, and predictors of benefit in neuromyelitis optica","volume":"77","author":"Costanzi","year":"2011","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.mcna.2012.05.001_bib47","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1212\/WNL.51.4.1219","article-title":"Devic's neuromyelitis optica: a prospective study of seven patients treated with prednisone and azathioprine","volume":"51","author":"Mandler","year":"1998","journal-title":"Neurology"},{"issue":"9","key":"10.1016\/j.mcna.2012.05.001_bib48","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1001\/archneurol.2010.203","article-title":"Neuromyelitis optica treatment: analysis of 36 patients","volume":"67","author":"Bichuetti","year":"2010","journal-title":"Arch Neurol"},{"issue":"2","key":"10.1016\/j.mcna.2012.05.001_bib49","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1177\/1756285611398939","article-title":"Current and future treatment approaches for neuromyelitis optica","volume":"4","author":"Collongues","year":"2011","journal-title":"Ther Adv Neurol Disord"},{"issue":"9","key":"10.1016\/j.mcna.2012.05.001_bib50","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1001\/archneurol.2009.175","article-title":"Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients","volume":"66","author":"Jacob","year":"2009","journal-title":"Arch Neurol"},{"issue":"7","key":"10.1016\/j.mcna.2012.05.001_bib51","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1212\/01.WNL.0000159399.81861.D5","article-title":"An open label study of the effects of rituximab in neuromyelitis optica","volume":"64","author":"Cree","year":"2005","journal-title":"Neurology"},{"issue":"11","key":"10.1016\/j.mcna.2012.05.001_bib52","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1001\/archneur.65.11.noc80069","article-title":"Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients","volume":"65","author":"Jacob","year":"2008","journal-title":"Arch Neurol"},{"issue":"7","key":"10.1016\/j.mcna.2012.05.001_bib53","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1001\/archneur.63.7.957","article-title":"Study of mitoxantrone for the treatment of recurrent neuromyelitis optica (Devic disease)","volume":"63","author":"Weinstock-Guttman","year":"2006","journal-title":"Arch Neurol"},{"issue":"4","key":"10.1016\/j.mcna.2012.05.001_bib54","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1001\/archneurol.2010.322","article-title":"Efficacy and safety of mitoxantrone in patients with highly relapsing neuromyelitis optica","volume":"68","author":"Kim","year":"2011","journal-title":"Arch Neurol"},{"issue":"7","key":"10.1016\/j.mcna.2012.05.001_bib55","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/ncprheum0818","article-title":"Optic neuritis and recurrent myelitis in a woman with systemic lupus erythematosus","volume":"4","author":"Birnbaum","year":"2008","journal-title":"Nat Clin Pract Rheumatol"},{"issue":"4","key":"10.1016\/j.mcna.2012.05.001_bib56","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1177\/08830738060210040701","article-title":"Devic disease in a child with primary Sjogren syndrome","volume":"21","author":"Arabshahi","year":"2006","journal-title":"J\u00a0Child Neurol"},{"issue":"1","key":"10.1016\/j.mcna.2012.05.001_bib57","first-page":"172","article-title":"Immunoablative cyclophosphamide for refractory lupus-related neuromyelitis optica","volume":"35","author":"Mok","year":"2008","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.mcna.2012.05.001_bib58","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD002277.pub3","article-title":"Intravenous immunoglobulin for myasthenia gravis","volume":"1","author":"Gajdos","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"10.1016\/j.mcna.2012.05.001_bib59","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1046\/j.1526-0968.2000.004004275.x","article-title":"Therapeutic apheresis in myasthenia gravis","volume":"4","author":"Batocchi","year":"2000","journal-title":"Ther Apher"},{"issue":"11","key":"10.1016\/j.mcna.2012.05.001_bib60","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1212\/01.wnl.0000256698.69121.45","article-title":"IV immunoglobulin in patients with myasthenia gravis: a randomized controlled trial","volume":"68","author":"Zinman","year":"2007","journal-title":"Neurology"},{"issue":"1-2","key":"10.1016\/j.mcna.2012.05.001_bib61","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.autneu.2008.11.001","article-title":"Immunotherapy for autoimmune autonomic ganglionopathy","volume":"146","author":"Iodice","year":"2009","journal-title":"Auton Neurosci"},{"issue":"15","key":"10.1016\/j.mcna.2012.05.001_bib62","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1056\/NEJMoa051719","article-title":"Plasma exchange for primary autoimmune autonomic failure","volume":"353","author":"Schroeder","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.mcna.2012.05.001_bib63","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD003279.pub2","article-title":"Treatment for Lambert-Eaton myasthenic syndrome","volume":"2","author":"Maddison","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"10.1016\/j.mcna.2012.05.001_bib64","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.nurt.2007.01.007","article-title":"Autoimmune and paraneoplastic channelopathies","volume":"4","author":"Vernino","year":"2007","journal-title":"Neurotherapeutics"},{"issue":"2","key":"10.1016\/j.mcna.2012.05.001_bib65","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1001\/archneurol.2007.60","article-title":"Combined immunomodulatory therapy in autoimmune autonomic ganglionopathy","volume":"65","author":"Gibbons","year":"2008","journal-title":"Arch Neurol"},{"issue":"10","key":"10.1016\/j.mcna.2012.05.001_bib66","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1517\/14656566.7.10.1323","article-title":"Available treatment options for the management of Lambert-Eaton myasthenic syndrome","volume":"7","author":"Verschuuren","year":"2006","journal-title":"Expert Opin Pharmacother"},{"issue":"2","key":"10.1016\/j.mcna.2012.05.001_bib67","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1056\/NEJM197401102900204","article-title":"Gradually increasing doses of prednisone in myasthenia gravis. Reducing the hazards of treatment","volume":"290","author":"Seybold","year":"1974","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.mcna.2012.05.001_bib68","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1212\/WNL.34.2.170","article-title":"Myasthenia gravis: prolonged treatment with steroids","volume":"34","author":"Sghirlanzoni","year":"1984","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.mcna.2012.05.001_bib69","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1055\/s-2004-829585","article-title":"Pathophysiology of myasthenia gravis","volume":"24","author":"Hughes","year":"2004","journal-title":"Semin Neurol"},{"issue":"6","key":"10.1016\/j.mcna.2012.05.001_bib70","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1212\/WNL.50.6.1778","article-title":"A\u00a0randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Myasthenia Gravis Study Group","volume":"50","author":"Palace","year":"1998","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.mcna.2012.05.001_bib71","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/ncpneuro0810","article-title":"Steroids and immunosuppressant drugs in myasthenia gravis","volume":"4","author":"Sathasivam","year":"2008","journal-title":"Nat Clin Pract Neurol"},{"issue":"3","key":"10.1016\/j.mcna.2012.05.001_bib72","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1002\/mus.20543","article-title":"Mycophenolate mofetil and tacrolimus: new therapeutic options in neuroimmunological diseases","volume":"34","author":"Schneider-Gold","year":"2006","journal-title":"Muscle Nerve"},{"issue":"2","key":"10.1016\/j.mcna.2012.05.001_bib73","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0022-510X(01)00478-6","article-title":"Mycophenolate (CellCept) treatment of myasthenia gravis, chronic inflammatory polyneuropathy and inclusion body myositis","volume":"185","author":"Mowzoon","year":"2001","journal-title":"J\u00a0Neurol Sci"},{"issue":"1","key":"10.1016\/j.mcna.2012.05.001_bib74","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1212\/WNL.56.1.94","article-title":"Mycophenolate mofetil: a safe and promising immunosuppressant in neuromuscular diseases","volume":"56","author":"Chaudhry","year":"2001","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.mcna.2012.05.001_bib75","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1215\/15228517-2007-004","article-title":"EBV-associated lymphoproliferative disorder of CNS associated with the use of mycophenolate mofetil","volume":"9","author":"O'Neill","year":"2007","journal-title":"Neuro Oncol"},{"issue":"6","key":"10.1016\/j.mcna.2012.05.001_bib76","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1212\/01.wnl.0000312374.95186.cc","article-title":"An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis","volume":"71","author":"Sanders","year":"2008","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.mcna.2012.05.001_bib77","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1212\/01.wnl.0000312373.67493.7f","article-title":"A\u00a0trial of mycophenolate mofetil with prednisone as initial immunotherapy in myasthenia gravis","volume":"71","year":"2008","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.mcna.2012.05.001_bib78","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1002\/mus.21640","article-title":"Mycophenolate mofetil in AChR-antibody-positive myasthenia gravis: outcomes in 102 patients","volume":"41","author":"Hehir","year":"2010","journal-title":"Muscle Nerve"},{"issue":"10","key":"10.1016\/j.mcna.2012.05.001_bib79","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1212\/01.WNL.0000094122.88929.0B","article-title":"Mycophenolate mofetil for myasthenia gravis: an analysis of efficacy, safety, and tolerability","volume":"61","author":"Meriggioli","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.mcna.2012.05.001_bib80","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1111\/j.1749-6632.1993.tb22937.x","article-title":"A\u00a0clinical therapeutic trial of cyclosporine in myasthenia gravis","volume":"681","author":"Tindall","year":"1993","journal-title":"Ann N Y Acad Sci"},{"issue":"12","key":"10.1016\/j.mcna.2012.05.001_bib81","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1056\/NEJM198703193161205","article-title":"Preliminary results of a double-blind, randomized, placebo-controlled trial of cyclosporine in myasthenia gravis","volume":"316","author":"Tindall","year":"1987","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.mcna.2012.05.001_bib82","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1212\/WNL.55.3.448","article-title":"Retrospective analysis of the use of cyclosporine in myasthenia gravis","volume":"55","author":"Ciafaloni","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.mcna.2012.05.001_bib83","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1196\/annals.1405.000","article-title":"Tacrolimus for myasthenia gravis: a clinical study of 212 patients","volume":"1132","author":"Ponseti","year":"2008","journal-title":"Ann N Y Acad Sci"},{"issue":"8","key":"10.1016\/j.mcna.2012.05.001_bib84","doi-asserted-by":"crossref","first-page":"731","DOI":"10.2169\/internalmedicine.47.0513","article-title":"Long-term treatment of steroid-dependent myasthenia gravis patients with low-dose tacrolimus","volume":"47","author":"Nagaishi","year":"2008","journal-title":"Intern Med"},{"issue":"1-2","key":"10.1016\/j.mcna.2012.05.001_bib85","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jns.2010.09.033","article-title":"Five-year follow-up with low-dose tacrolimus in patients with myasthenia gravis","volume":"300","author":"Minami","year":"2011","journal-title":"J\u00a0Neurol Sci"},{"issue":"9","key":"10.1016\/j.mcna.2012.05.001_bib86","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1136\/jnnp-2011-300148","article-title":"Randomised, double-blind, placebo-controlled study of tacrolimus in myasthenia gravis","volume":"82","author":"Yoshikawa","year":"2011","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"issue":"1","key":"10.1016\/j.mcna.2012.05.001_bib87","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/mus.10133","article-title":"Use of intravenous pulsed cyclophosphamide in severe, generalized myasthenia gravis","volume":"26","author":"De Feo","year":"2002","journal-title":"Muscle Nerve"},{"issue":"1","key":"10.1016\/j.mcna.2012.05.001_bib88","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/ana.10400","article-title":"Treatment of refractory myasthenia: \u201crebooting\u201d with high-dose cyclophosphamide","volume":"53","author":"Drachman","year":"2003","journal-title":"Ann Neurol"},{"issue":"6","key":"10.1016\/j.mcna.2012.05.001_bib89","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1136\/jnnp.2009.197632","article-title":"The use of rituximab in myasthenia gravis and Lambert-Eaton myasthenic syndrome","volume":"82","author":"Maddison","year":"2011","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"issue":"3","key":"10.1016\/j.mcna.2012.05.001_bib90","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1002\/mus.21521","article-title":"Rituximab in the management of refractory myasthenia gravis","volume":"41","author":"Zebardast","year":"2010","journal-title":"Muscle Nerve"},{"issue":"2","key":"10.1016\/j.mcna.2012.05.001_bib91","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/j.1468-1331.2008.02399.x","article-title":"Successful treatment of refractory generalized myasthenia gravis with rituximab","volume":"16","author":"Lebrun","year":"2009","journal-title":"Eur J Neurol"},{"issue":"4","key":"10.1016\/j.mcna.2012.05.001_bib92","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s10286-009-0012-7","article-title":"Autoimmune autonomic ganglionopathy: treatment by plasma exchanges and rituximab","volume":"19","author":"Imrich","year":"2009","journal-title":"Clin Auton Res"},{"issue":"27","key":"10.1016\/j.mcna.2012.05.001_bib93","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1056\/NEJM199312303292704","article-title":"A\u00a0controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis","volume":"329","author":"Dalakas","year":"1993","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.mcna.2012.05.001_bib94","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1136\/jnnp.65.1.107","article-title":"Immunoglobulin therapy in inflammatory myopathies","volume":"65","author":"Mastaglia","year":"1998","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"issue":"5","key":"10.1016\/j.mcna.2012.05.001_bib95","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1212\/WNL.43.5.876","article-title":"Treatment of inclusion-body myositis with high-dose intravenous immunoglobulin","volume":"43","author":"Soueidan","year":"1993","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.mcna.2012.05.001_bib96","first-page":"22","article-title":"High-dose immunoglobulin therapy in sporadic inclusion body myositis: a double-blind, placebo-controlled study","volume":"247","author":"Walter","year":"2000","journal-title":"J\u00a0Neurol"},{"issue":"8","key":"10.1016\/j.mcna.2012.05.001_bib97","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1212\/WNL.35.8.1105","article-title":"Plasmapheresis in Guillain-Barr\u00e9 syndrome","volume":"35","author":"Dyck","year":"1985","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.mcna.2012.05.001_bib98","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1002\/ana.410360607","article-title":"A\u00a0plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy","volume":"36","author":"Dyck","year":"1994","journal-title":"Ann Neurol"},{"issue":"8","key":"10.1016\/j.mcna.2012.05.001_bib99","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1056\/NEJM198602203140801","article-title":"Plasma exchange in chronic inflammatory demyelinating polyradiculoneuropathy","volume":"314","author":"Dyck","year":"1986","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.mcna.2012.05.001_bib100","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1212\/WNL.56.4.445","article-title":"Randomized controlled trial of IVIg in untreated chronic inflammatory demyelinating polyradiculoneuropathy","volume":"56","author":"Mendell","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/j.mcna.2012.05.001_bib101","first-page":"585","article-title":"Encephalopathy associated with Hashimoto thyroiditis: diagnosis and treatment","volume":"243","author":"Kothbauer-Margreiter","year":"1996","journal-title":"J\u00a0Neurol"},{"issue":"Suppl 3","key":"10.1016\/j.mcna.2012.05.001_bib102","first-page":"A248","article-title":"Steroid-responsive encephalopathy associated with thyroid autoimmunity: clinical and laboratory findings","volume":"58","author":"Castillo","year":"2002","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.mcna.2012.05.001_bib103","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1001\/archneur.63.2.197","article-title":"Steroid-responsive encephalopathy associated with autoimmune thyroiditis","volume":"63","author":"Castillo","year":"2006","journal-title":"Arch Neurol"},{"issue":"1","key":"10.1016\/j.mcna.2012.05.001_bib104","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1212\/01.WNL.0000148580.98997.C5","article-title":"Effects of prednisone and plasma exchange on cognitive impairment in Hashimoto encephalopathy","volume":"64","author":"Hussain","year":"2005","journal-title":"Neurology"},{"issue":"16","key":"10.1016\/j.mcna.2012.05.001_bib105","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1056\/NEJMra023009","article-title":"Paraneoplastic syndromes involving the nervous system","volume":"349","author":"Darnell","year":"2003","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.mcna.2012.05.001_bib106","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1111\/j.1468-1331.2006.01266.x","article-title":"Management of paraneoplastic neurological syndromes: report of an EFNS Task Force","volume":"13","author":"Vedeler","year":"2006","journal-title":"Eur J Neurol"},{"issue":"1","key":"10.1016\/j.mcna.2012.05.001_bib107","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/0303-8467(95)00003-3","article-title":"Anti-tumour therapy in paraneoplastic neurological disease","volume":"97","author":"Grisold","year":"1995","journal-title":"Clin Neurol Neurosurg"},{"key":"10.1016\/j.mcna.2012.05.001_bib108","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1146\/annurev.med.48.1.157","article-title":"Paraneoplastic syndromes affecting the central nervous system","volume":"48","author":"Posner","year":"1997","journal-title":"Annu Rev Med"},{"issue":"Pt 6","key":"10.1016\/j.mcna.2012.05.001_bib109","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1093\/brain\/awg133","article-title":"Paraneoplastic cerebellar degeneration associated with antineuronal antibodies: analysis of 50 patients","volume":"126","author":"Shams'ili","year":"2003","journal-title":"Brain"},{"issue":"1","key":"10.1016\/j.mcna.2012.05.001_bib110","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/ana.21050","article-title":"Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma","volume":"61","author":"Dalmau","year":"2007","journal-title":"Ann Neurol"},{"issue":"1","key":"10.1016\/j.mcna.2012.05.001_bib111","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s11910-996-0012-0","article-title":"Current therapies for neuromuscular manifestations of paraneoplastic syndromes","volume":"6","author":"Rosenfeld","year":"2006","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"4","key":"10.1016\/j.mcna.2012.05.001_bib112","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1136\/jnnp.68.4.479","article-title":"Treatment of paraneoplastic neurological syndromes with antineuronal antibodies (Anti-Hu, anti-Yo) with a combination of immunoglobulins, cyclophosphamide, and methylprednisolone","volume":"68","author":"Keime-Guibert","year":"2000","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"issue":"4","key":"10.1016\/j.mcna.2012.05.001_bib113","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1136\/jnnp.60.4.388","article-title":"Intravenous immunoglobulin treatment in paraneoplastic neurological syndromes with antineuronal autoantibodies","volume":"60","author":"Uchuya","year":"1996","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.mcna.2012.05.001_bib114","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1215\/S1152851703000395","article-title":"Immunomodulatory treatment trial for paraneoplastic neurological disorders","volume":"6","author":"Vernino","year":"2004","journal-title":"Neuro Oncol"},{"issue":"1","key":"10.1016\/j.mcna.2012.05.001_bib115","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1002\/1531-8249(200001)47:1<9::AID-ANA5>3.0.CO;2-I","article-title":"Detection and treatment of activated T cells in the cerebrospinal fluid of patients with paraneoplastic cerebellar degeneration","volume":"47","author":"Albert","year":"2000","journal-title":"Ann Neurol"},{"issue":"2","key":"10.1016\/j.mcna.2012.05.001_bib116","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1002\/pbc.20899","article-title":"Response to rituximab in a child with neuroblastoma and opsoclonus-myoclonus","volume":"50","author":"Bell","year":"2008","journal-title":"Pediatr Blood Cancer"},{"issue":"3","key":"10.1016\/j.mcna.2012.05.001_bib117","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s11060-007-9479-z","article-title":"Successful treatment of paraneoplastic cerebellar degeneration with rituximab","volume":"86","author":"Esposito","year":"2008","journal-title":"J\u00a0Neurooncol"},{"issue":"1","key":"10.1016\/j.mcna.2012.05.001_bib118","first-page":"16","article-title":"An uncontrolled trial of rituximab for antibody associated paraneoplastic neurological syndromes","volume":"253","author":"Shams'ili","year":"2006","journal-title":"J\u00a0Neurol"},{"issue":"Suppl 1","key":"10.1016\/j.mcna.2012.05.001_bib119","first-page":"I19","article-title":"The role of IVIg in the treatment of patients with stiff person syndrome and other neurological diseases associated with anti-GAD antibodies","volume":"252","author":"Dalakas","year":"2005","journal-title":"J\u00a0Neurol"},{"issue":"7","key":"10.1016\/j.mcna.2012.05.001_bib120","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1136\/jnnp.2004.051144","article-title":"Treatment of stiff person syndrome with rituximab","volume":"76","author":"Baker","year":"2005","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"}],"container-title":["Medical Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025712512000806?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025712512000806?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,30]],"date-time":"2019-06-30T01:19:33Z","timestamp":1561857573000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025712512000806"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5]]},"references-count":120,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,5]]}},"alternative-id":["S0025712512000806"],"URL":"https:\/\/doi.org\/10.1016\/j.mcna.2012.05.001","relation":{},"ISSN":["0025-7125"],"issn-type":[{"value":"0025-7125","type":"print"}],"subject":[],"published":{"date-parts":[[2012,5]]}}}